Introduction
The current paradigm of rheumatoid arthritis (RA) pathogenesis emphasizes the development of a systemic autoimmune response that leads to persistent synovial inflammation and progressive joint destruction. Autoimmunity may be triggered at mucosal surfaces, and serologic evidence suggests that asymptomatic immune dysregulation can exist for many years before joint inflammation becomes clinically evident (1) . The inflamed synovium ultimately becomes hyperplastic and develops into the pathologic hallmark of RA-a synovial pannus with invasive properties that comprises infiltrating leukocytes and germinal centers, proliferating fibroblast-like synoviocytes (FLS), and neovasculature. As the major component of hyperplastic pannus, FLS actively participate in joint inflammation and in cartilage and bone destruction by both contact-dependent interactions and the production of inflammatory mediators and matrix-degrading enzymes (2) . FLS in RA resist apoptosis, show increased adhesive and invasive properties, escape contact inhibition, and can seed, infiltrate, and damage joints in immunodeficient mice (3) (4) (5) (6) . Notably, this aggressive phenotype endures after multiple cell passages in vitro, suggesting that FLS are persistently, if not irreversibly, altered in the rheumatoid joint.
Pannus development has long been noted to be central to joint destruction, but why it develops in RA and not in other autoimmune arthritides is unknown (7) . The molecular basis of pannus formation and the pathways by which synovial fibroblasts achieve and maintain an aggressive phenotype, even after removal from the articular milieu, are not fundamentally understood but are so tumor-like in character as to have been compared to a locally invasive cancer (8, 9) . Indeed, there is evidence of both protooncogene activation and functional or mutational inactivation of tumor suppressor genes in rheumatoid FLS (2) . The molecular signatures and biologic networks that define the distinct pathology of rheumatoid FLS have not been systematically explored, but a leading notion is that absent oncogenic transformation, such phenotypic maintenance results from self-perpetuating or re-entrant stimulatory pathways involving autocrine intermediation and sustained intracellular signaling.
Pannus supports immune cell recruitment, germinal center formation, and localized autoantibody production, and may provide the necessary microenvironment to sustain autoimmunity and joint destruction. Better knowledge of the pathways underlying the aggressive phenotype of FLS would facilitate experimental study and potential therapeutic targeting. RA remains incurable, and whether current therapies adequately suppress synovial pathology is unclear. The connective tissue origin of FLS may render them intrinsically resistant to immunosuppression, but interfering in their proliferative and invasive character could contribute significantly to a more effective treatment regimen.
In this review, we describe the current state of knowledge on the molecular alterations in rheumatoid FLS at the genomic, epigenomic, transcriptomic, proteomic, and metabolomic levels. To date, molecular profiling in RA has been carried out mainly in immune cells. We suggest that a comprehensive and complementary investigation of "omics" data in rheumatoid FLS, in combination with interrogation of data sets available for other cell types (10, 11) including from premalignant and malignant tissues, may enable the identification of the key molecular signatures for RA-specific joint destruction.
Search strategy and study selection criteria
We searched PubMed using the terms "fibroblast" and "synoviocytes" and "fibroblast-like synoviocytes." Studies relevant to RA were identified using the term "rheumatoid arthritis." Our search included 2,779 articles published from 1980 through June 2017.
Genetic control of rheumatoid synoviocytes
Genetic variation in germline DNA, particularly within loci that influence immune responsiveness, contributes to RA susceptibility and to the clinical expression of disease. HLA alleles that are essential for antigen presentation and T cell repertoire selection feature prominently in disease susceptibility in ethnically diverse populations in which RA develops (12) . Genetic variation in the HLA-DRB1 locus that defines a "shared epitope," a 5-amino acid motif in the third allelic hypervariable region of the HLA-DRb molecule, is the most highly associated with RA and is present in almost 60% of subjects in some studies (13) . Nevertheless, the genetic contribution of this and other germline alleles to RA susceptibility is tempered by observations in genetically related siblings; for instance, among monozygotic twins, the concordance rate for RA is only 15% (14) . Such low concordance, as in other autoimmune diseases, has been interpreted as supporting the more important role of environmental or stochastic factors in ultimate development of disease. The most welldescribed environmental factors in RA include smoking, stress, and infection (1) . Smoking perturbs mucosal immunity and promotes protein modification (e.g., citrullination, carbamylation) that induces autoantigens that may directly trigger HLA shared epitope autoimmunity (15) . Circulating and persistent anti-citrullinated protein autoantibodies (ACPAs) presage disease development by up to 10 years (16, 17) . Smoking also increases the clinical severity of RA in individuals with the HLA shared epitope (13, 18) . Repeated exposure to stress or to infection may dysregulate inflammatory responses, lower immune tolerance, and trigger autoimmunity, although mechanisms that may be specific to RA have eluded precise definition.
Persistent but subclinical inflammatory activation of the synovium, mediated by ACPA-or rheumatoid factor-containing immune complexes together with localized inflammatory mediator expression, contributes to genotoxicity. Oncogenic mutation is well known to occur at sites of chronic inflammation, e.g., in inflammatory bowel disease, Barrett's esophagitis, Helicobacter gastritis, chronic pancreatitis, hepatitis, and other conditions (19) . Reactive oxygen species (ROS) and reactive nitrogen species are mutagenic and are persistently up-regulated in rheumatoid FLS (Figure 1 ). There is evidence that somatic mutations occur in synoviocytes, contributing to growth dysregulation and an invasive phenotype. Mutations in protooncogenes such as P53 and RAF1 and in mitochondrial DNA have been reported in rheumatoid FLS; while these are insufficient for oncogenesis and malignant transformation, they dysregulate DNA repair, perturb cell cycle control, and can activate mutS homolog genes to increase microsatellite instability and further gene variation (20) . Such changes increase synoviocyte survival in the presence of inflammatory signals by bypassing cell cycle arrest and promote an aggressive phenotype that contributes to pannus formation. Interestingly, synovial mutations in P53 show a pathologic spatial heterogeneity; they are detectable in intimal lining cells that are most closely apposed to areas of cartilage destruction (21) . As in the case of the tumor microenvironment, it is conceivable that multiple and distinct populations of rheumatoid FLS emerge. Indeed, recent studies have identified distinct molecular profiles in FLS from different anatomic sites (22) (23) (24) (25) (26) . In concert with infiltrating immune cells, rheumatoid FLS sustain the signaling interactions necessary for autoimmunity and expression of the full phenotypic features of rheumatoid pannus.
To date, investigation of somatic mutations in synovial fibroblasts has relied largely on candidate gene approaches derived from cancer data. Genome-wide association studies (GWAS) have revealed a large number of single-nucleotide polymorphisms (SNPs) associated with RA; however, genetic markers that might be associated with synoviocyte phenotypes have not been comprehensively assessed (27) . Only a few studies have identified genes whose variants may influence FLS function (28) (29) (30) (31) (32) . 638 YOU ET AL
The genomic locus of the SPAG16 gene (rs7607479) is associated with radiologic progression in RA, and FLS encoding the SPAG16 minor allele secrete reduced amounts of matrix metalloproteinase 3 (MMP-3) (28) . Risk SNPs in synoviocyte DNA that have not been annotated in leukocyte DNA also have been reported (29) . A SNP (rs10175798) proximal to the LBH gene may regulate synoviocyte proliferation (30) , and a SNP (rs1800795) in the proximal promoter of IL6 influences interleukin-6 (IL-6) expression in synoviocytes but not in CD14+ monocytes (27) . Recently, Yoo et al reported distinct pathologic phenotypes among rheumatoid FLS encoding a high-expression variant of the MIF gene (rs5844572) (32) , which is a common risk allele for erosive RA (33, 34) . Rheumatoid FLS with high-expression MIF promoter variants exhibit up-regulation of an inflammatory and invasive phenotype, with enhanced recruitment of the macrophage migration inhibitory factor (MIF) signaling receptor (CD44) into a functional signal transduction complex and alternative exon splicing to produce invasive CD44v3-v6 isoforms associated with oncogenic progression (28) . Beyond activating invasion, MIF recapitulates other cardinal features of malignant transformation, including resistance to apoptosis, proliferative signaling, evasion of growth suppressors, and angiogenesis (35) (36) (37) . A treatment strategy using an anti-MIF receptor (e.g., milatuzumab) could be rationally considered for RA, particularly in those individuals found to carry high-expression MIF alleles. While further study is needed, synoviocyte-specific gene associations based on rheumatoid FLS DNA could allow for improved pathogenic insight and for identifying pathways to treat invasive pannus. One attraction of this approach would be pharmacologic targeting of invasive or growth-regulating processes that could be non-overlapping in action or toxicity with concurrent immunosuppression treatment. 
Epigenetic control of rheumatoid synoviocytes
Rheumatoid FLS exhibit unique pathologic characteristics that include 1) secretion of proinflammatory cytokines, prostanoids, and proangiogenic factors (7, (38) (39) (40) , 2) enhanced proliferation and survival, and 3) invasive character via the expression of MMPs and adhesion molecules that bind extracellular components such as integrins and CD44 (41) (42) (43) (44) (45) . These features are cell intrinsic, and their persistence in isolated cell culture has prompted a search for causative epigenetic modifications (Figure 2 ). Epigenetic modification through DNA methylation or histone modification (e.g., acetylation, methylation, and sumoylation) modulates DNA accessibility to transcriptional regulator complexes. Rheumatoid FLS DNA is broadly hypomethylated across the genome (46), histone acetylation is increased (47) , and specific microRNAs (miRNAs) are up-regulated (48) .
Global genomic hypomethylation in particular is considered to have a role in RA pathogenesis, and studies have shown that the expression of DNMT1 (DNA methyltransferase 1) is reduced in rheumatoid FLS (46) . There is increased expression of genes for enzymes that are necessary for demethylation, including AMD1 (S-adenosyl methionine decarboxylase 1), SSAT1 (spermidine/spermine N1-acetyltransferase), and PMFBP1 (polyaminemodulated factor 1-binding protein 1), together with reduced expression of SAM (S-adenosyl methionine) and 5-MeC (nuclear 5-methylcytosine), in rheumatoid FLS compared to osteoarthritic FLS (49) . Genome-wide profiling studies of epigenetic histone modifications remain limited, however. Nakano et al (50) described 1,859 differentially methylated loci in rheumatoid FLS, and with respect to specific target genes, a reduction in the methylation of promoters for the proinflammatory cytokines IL6 (51) and CXCL12 (52) has been reported ( Figure 2) . DNA hypomethylation could alter the expression of genes that are relevant to joint pathology, including those necessary for synovial invasiveness, by enhancing migratory activity and extracellular matrix interactions (50) .
Tumor necrosis factor (TNF) increases the expression of HDAC1 and nuclear histone deacetylase (HDAC) activity in FLS, suggesting that the histone deacetylation observed in rheumatoid synovium results from inflammatory signaling (53) . Niederer et al (54) also demonstrated that the histone deacetylase sirtuin 1 is overexpressed in RA synovium and that expression levels are further increased by stimulation with TNF. Sirtuin 1 in turn enhances production of the proinflammatory cytokines IL-6 and IL-8, and promotes synoviocyte survival (Figure 2 ). Other histone modifications such as methylation, ubiquitination, and sumoylation have been examined in rheumatoid synoviocytes. Trenkmann et al demonstrated that EZH2 (enhancer of zeste homolog 2), a histone methyltransferase, is overexpressed (55) and identified SFRP1 (secreted Frizzled-related protein 1), an inhibitor of Wnt 
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signaling, as a downstream target of EZH2. Those authors further showed that SFRP1 expression correlates with promoter occupation and with activating and silencing histone marks (55) . Rheumatoid FLS have intrinsically high levels of SUMO1 (the enzyme small ubiquitin-like modifier 1) and consequently low levels of its unique protease SENP1 (56) . Transient overexpression of SENP1 in FLS reduces H4 acetylation in the MMP1 promoter and MMP1 expression (Figure 2 ), which is consistent with the notion that histone sumoylation contributes to the local invasiveness of rheumatoid FLS. Noncoding RNA (ncRNA), including miRNA and long noncoding RNA (lncRNA), is an epigenetic regulatory mechanism that imparts broad and long-term changes in gene expression. In Table 1 , miRNAs and lncRNAs are categorized according to 3 major pathologic features of rheumatoid FLS: 1) inflammation, 2) proliferation and survival, and 3) tissue invasiveness, and the common functional roles of ncRNAs identified both in rheumatoid FLS and in cancer cells (57) (58) (59) (60) are highlighted. MicroRNA 221 (miR-221), for instance, is overexpressed in both cell types; it promotes tissue invasiveness by up-regulating MMPs in rheumatoid FLS (57, 58, 61) and it increases the migration of metastatic cancer cells (62, 63) . This similarity in expression and function supports the notion that this miRNA has a potential role in the tumor-like dedifferentiation and invasive character of rheumatoid FLS.
There are nevertheless limitations to such comparisons, as the expression and role of ncRNAs are not always coincident between rheumatoid FLS and cancer cells. For example, miR-203 is up-regulated in FLS and promotes MMP-1 and IL-6 production, but it is down-regulated in several cancers (64) (65) (66) and it suppresses the proliferation and invasiveness of melanoma cells (67) . Forced expression of HOTAIR (homeobox antisense intergenic RNA), a lncRNA, decreases MMP-2 and MMP-13 levels in rheumatoid FLS (68) but its expression is elevated in some types of cancer, in which it reprograms chromatin to increase tumor invasiveness and metastasis (69) . Additional examples of discrepancies include miR-143 and miR-145, which are highly expressed in rheumatoid FLS (70) . These 2 miRNAs increase NF-jB activity and IL-6 production by regulating IGFBP5 and promote FLS survival by suppressing SEMA3A (70), but they are down-regulated in multiple cancer types (71, 72) . The differential expression and functional role of ncRNAs thus raises the possibility that FLS exhibit distinct epigenetic regulatory mechanism(s) to sustain their proliferative and invasive properties. It is exceedingly rare for rheumatoid synovia to transform into cancer, suggesting that even with mutations in P53 or other protooncogenes, distinct cell-or tissue-specific regulatory mechanisms prevent oncogenic progression.
Integrative approaches for defining pathologic signatures in rheumatoid synoviocytes
The development of high-throughput technologies such as microarray-based expression analyses and nextgeneration sequencing has enabled collection of an unprecedented quantity of information from clinical and biologic samples. The integration of different "omics" data by statistical informatics also has the potential to provide for a holistic understanding of pathologic processes (24, 27, 73) . Transcriptome, epigenome, and proteome data have been generated from FLS from independent studies, opening opportunities for defining signatures for rheumatoid pannus. Whitaker et al recently performed an integrated analysis of SNPs identified by GWAS with transcriptome and methylome data derived from rheumatoid FLS (74) . They identified a significant enrichment of "multi-evidence" genes (MEGs) related to RA pathogenicity, such as ELMO1 (cell motility protein 1), which is overexpressed, promotes cell migration and invasion, and regulates Rac1 GTPase activity that is essential for cytoskeletal dynamics and motility.
For the purposes of this review, we performed a comparative analysis of available genomic, transcriptome, methylome, and proteome data (75) (76) (77) (78) (79) (80) to identify genes and proteins that are altered in rheumatoid synoviocytes ( Figure 3A) . Notably, only a few genes were found to coincide by simple pairwise comparison of these databases, with the exception of the differentially expressed genes (DEGs) and differentially methylated genes (DMGs). Proteome data would be expected to reflect transcriptome and methylome signatures, and it is not evident why data on differentially regulated proteins from 5 independent studies did not overlap with DEGs and DMGs in this analysis. The queried databases may be compromised by individual cell-or data-specific profiles and limited by disease stage (early versus longstanding) (81), clinical activity, drug treatment, or selection bias due to the small number of tested samples. More precise and uniform clinical phenotyping, greater sample sizes, and an integrated biostatistical approach are desirable to resolve this individual variability.
To what degree might genetic variation at the DNA level impact the transcriptome, methylome, and proteome signatures of rheumatoid synoviocytes? We examined whether SNPs identified from GWAS coincide with genes identified by other omics approaches ( Figure 3B ). As there is no GWAS catalog of synoviocyte DNA, our query was limited to SNP data from peripheral leukocyte DNA (27) . Fewer than 20% of SNPs coincided with genes or proteins discovered by the other omics profiles, indicating that the genetic variation represented by SNPs, or their 642 YOU ET AL tagged genes, does not contribute significantly to the pathologic signatures of rheumatoid FLS. A similar analysis performed after excluding the GWAS data also showed that <30% of genes coincided in a one-to-one comparison between 2 or more omics data sets ( Figure 3C ). These findings again suggest appreciable individual heterogeneity, bias, or inherent limitations in the gene/protein scoring methodologies. To complete this multidimensional analytic approach, we selected 306 MEGs that were identified in 2 or more of the omics databases (see Supplementary Table  1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40406/ abstract) and conducted a functional enrichment analysis of the genes using DAVID software version 6.8 (82) . The synovial pathologies of inflammation, proliferation/survival, and invasiveness (cell adhesion, migration, and extracellular matrix organization) were enriched according to this analysis ( Figure 3D ). To a certain extent, this finding supports the value of an integrated MEG approach to analyzing such data, although the representational content and quality of the collected omics data sets remain a limiting issue (74) . The goal nevertheless would be to apply multidimensional analysis of molecular profiling data to identify disease-relevant signatures and facilitate the discovery of coherent pathways for pathologic insight and therapeutic targeting.
Metabolic dysregulation and metabolomics in rheumatoid synovium
It is reasonable to presume that the sustained activation of rheumatoid synoviocytes leads to an altered metabolic profile and a characteristic signature that can be discerned by metabolomic analysis. Metabolite changes have been described in the serum, urine, and synovial fluid of RA patients, and include both changes in amino acid and lipid metabolism and a dysregulation in glycolysis with increased lactate production (83-85) that has been attributed to the tumor-like phenomenon of aerobic glycolysis, or the Warburg effect (86) . Aerobic glycolysis characterizes . Differentially expressed genes (DEGs) were first screened using transcriptome data on FLS from patients with rheumatoid arthritis (RA) and patients with osteoarthritis (OA) (80) . Next, the differentially methylated gene (DMG) signature was obtained (74) . Finally, a list of 257 differentially regulated proteins (DRPs) with significant differences in expression or phosphorylation in RA FLS versus OA FLS was generated by combining DRPs from 5 independent studies (75-79). Single-nucleotide polymorphisms (SNPs) identified from genome-wide association studies (GWAS), DEGs, DMGs, and DRPs were compared to identify overlapping and unique genes and proteins. A, Number of common and distinct genes that were detected or differentially expressed in rheumatoid FLS by these comparisons. B, Proportion of overlapping genes harboring RA-associated SNPs in comparison to the proteome, methylome, or transcriptome of rheumatoid FLS. C, Percentage of overlapping or non-overlapping genes between at least 2 different levels of omics data. D, Functional enrichment analysis of the genes that were overlapping between at least 2 different levels of omics data.
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A number of studies have demonstrated altered metabolism in rheumatoid FLS, with implications for inflammatory joint damage (89) (90) (91) (92) . Garcia-Carbonell et al showed that platelet-derived growth factor (PDGF) increases glucose metabolism and glucose transporter 1 expression in rheumatoid synoviocytes and that inhibition of glycolysis mitigates inflammatory cytokine secretion, proliferation, and migration by FLS and reduces joint damage in vivo (90) . A parallel study demonstrated that hypoxic stimuli drive synoviocytes to up-regulate glycolysis, promote invasion, and stimulate angiogenic pathways, and that inhibition of glycolysis reduces inflammatory cytokine secretion, migration, and invasion of rheumatoid FLS, and endothelial tube formation (91) . Inflammation and ROSinduced mitochondrial DNA damage can mutate the mitochondrial genome, leading to electron transport and respiratory chain dysfunction (93) . Mitochondrial dysfunction in turn promotes ROS production and energy depletion which, if unresolved, may activate autophagy and cell death pathways (94) . Metabolic intermediates generated through the mitochondrial tricarboxylic acid cycle differ between RA patients and healthy individuals (89) . Among the 306 MEGs defined in the 2-way database comparisons, genes or gene products were selected using DAVID geneKyoto Encyclopedia of Genes and Genomes pathway information to identify those associated with energy metabolism (Table 2 and Supplementary Figure 1 , on the Arthritis & Rheumatology web site at http://online library.wiley.com/doi/10.1002/art.40406/abstract). Increased expression of NAMPT (nicotinamide phosphoribosyltransferase), which maintains NAD levels under stress conditions and is increased in expression in rheumatoid FLS and in the joints and serum of mice with collagen-induced arthritis, was noted (95) .
Abnormalities in choline metabolism are a feature of oncogenesis and tumor progression (96) . Choline kinase, which catalyzes phosphatidylcholine biosynthesis, is expressed in RA synovium, and is induced by stimulation with TNF or PDGF (97) . Inhibition of choline kinase represses the aggressive behavior of rheumatoid FLS and attenuates disease in mice with serum-transfer arthritis (97). In-28H1). After 24 hours, radiotracer uptake (arrows) is clearly visible in the inflamed joints of a mouse with CIA (E), but not in a control mouse (F). Three-dimensional SPECT/CT scans using 99m Tc-labeled FAP antibody also reveal that increased radiotracer uptake in the joints of an arthritic mouse (G) (arrows) was reduced by treatment with prednisolone (H). The images in E and F are reproduced from reference 103 (copyright Society of Nuclear Medicine and Molecular Imaging, Inc.), with permission. The images in G and H are reproduced from reference 104 (copyright Society of Nuclear Medicine and Molecular Imaging, Inc.), with permission.
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Current data suggest a dysregulation in synoviocyte metabolism in RA, with a shift away from oxidative phosphorylation and toward aerobic glycolysis that is reminiscent of transformed cells. Presumably, this phenotype ensues from chronic inflammatory stimulation by cytokines, ROS, and hypoxia, and dysregulated metabolism correlates with mitochondrial dysfunction and DNA damage. Such metabolic abnormalities likely support the invasive phenotype of the rheumatoid synovium and may offer diagnostic biomarker and therapeutic opportunities for targeting rheumatoid FLS without affecting the overall immune repertoire.
Diagnostic applications
The hyperplasia and dedifferentiation of FLS within the rheumatoid joint are accompanied by a neo-angiogenic response to produce the fibrovascular changes characteristic of pannus. Unique morphologic features of grossly inflamed synovial tissues, such as edematous villous projections in the joint cavity, can be visualized by ultrasound (US) and magnetic resonance imaging (MRI). Gray-scale and Doppler US measure synovial proliferation and increased vascularity, respectively ( Figures 4A and B) . Synovial hypertrophy can be defined by US as hyperechoic intraarticular tissue that is nondisplaceable and poorly compressible, and with an enhanced Doppler signal (98) . Notably, findings on color Doppler US imaging show positive correlations with quantitative immunohistochemical staining for von Willebrand factor, CD3, CD68, and Ki-67 in synovial biopsy specimens (99) . MRI using gadolinium contrast enhancement allows visualization of synovitis as a thickened synovial compartment with abovenormal post-gadolinium enhancement (100) (Figure 4C ).
US and MRI are powerful diagnostic tools for the early diagnosis of synovial disease and predict radiographic progression and joint erosion in early undifferentiated arthritis (101, 102) . These techniques cannot be used to assess functional abnormalities, however, which may have added diagnostic or prognostic utility. Positron emission tomography (PET) scanning is sensitive to glucose-dependent metabolic processes (91) (Figure 4D ). The combination of immuno-PET or immuno-single-photon-emission computed tomography using radiolabeled anti-fibroblast activation protein antibody enables visualization of arthritic joints with high resolution and accurate measurement of inflammation severity and treatment response in murine arthritis (103, 104) (Figures 4E-H) .
Prospects for therapeutic strategies targeting rheumatoid synovium and FLS
Newly approved therapies that target the immune system offer effective disease control, albeit with risk of infection and malignancy. While clinical remission is now more readily achieved, an appreciable percentage of patients experience incomplete responses or refractory disease. There also is no cure for RA despite continuing clinical trial efforts with new and combination immunotherapies. Pharmacologic targeting of the rheumatoid pannus may be considered to be an attractive strategy for several reasons. The chronic inflammatory microenvironment driven by FLS may perpetuate autoimmunity by ongoing autoantigen presentation, costimulatory cytokine production, and the maintenance of autoantibody-producing germinal centers. Recurrent or refractory disease may depend on immunopathologic interactions that are spatially coordinated within pannus stroma, and such effects may be analogous to the tumor microenvironment, although in the case of RA the interactions are immunostimulatory rather than immunosuppressive. Synovial-based interventions could offer an approach to more effective and long-term disease control by disrupting synoviocyte-specific immunopathology. Moreover, interference with proliferating and invasive synoviocytes may prevent the destruction of articular cartilage and subchondral bone by mechanisms that do not contribute to systemic immunosuppression and adverse events.
One approach that has been pursued, by analogy to antitumor pharmacology, is suppression of synovial angiogenesis. Notably, effects of anti-TNF therapy include reduction of serum concentrations of the angiogenic mediator vascular endothelial growth factor (VEGF) (105) and reduction of synovial blood flow and vascularity (106) . Therapeutic inhibition of the VEGF pathway has been studied in preclinical models of inflammatory arthritis, under the hypothesis that vasculogenesis is essential for the expansion and maintenance of pannus tissue. The anti-VEGF antibody bevacizumab reduces arthritis and synovial injury to a similar degree as TNF inhibition when studied in a collageninduced arthritis rat model (107) . Interference with VEGF receptor action by neutralizing antibody or by inhibition of downstream kinase signaling also ameliorates disease in preclinical models (108, 109) , and similar treatment effects were reported with the angiogenesis inhibitor endostatin (110) .
Given the wealth of evidence implicating FLS in perpetuating synovial inflammation and destroying articular cartilage and subchondral bone, could FLS be selectively targeted? Ideally, unique or cell-specific markers for these cells could be used for an immune targeting or cell depletion strategy. We explored the omics databases to identify genes that show specificity for expression in rheumatoid FLS (Table 3 and Supplementary Figure 2 Examination of GTEx (Genotype-Tissue Expression database) using criteria that the gene is 1) increased 646 YOU ET AL in expression in rheumatoid FLS and has potential pathologic significance and 2) is rarely expressed in other cell types yielded several candidates. FAP (fibroblast activation protein) and GREM1 (gremlin 1) were classified as highly specific for rheumatoid FLS, CDH11 (cadherin 11) and THY1 (thymocyte differentiation antigen 1) as moderately specific, and ICAM1 (intracellular adhesion molecule 1) and CD55 as having low cell specificity. GREM1 is an antagonist of bone morphogenetic protein and regulates the survival, proliferation, migration, and invasion of rheumatoid FLS (111) . FAP encodes a type II membrane serine protease that is highly expressed in rheumatoid synovium and contributes to the myofibroblastic phenotype of synoviocytes (26, 112) . Notably, CDH11, which mediates homophilic cell adhesion, has been well studied in synovium for its ability to regulate synovial morphogenesis and fibroblast proinflammatory function. Cdh11-deficient mice have hypoplastic synovia and show reduced inflammation and cartilage erosion when challenged in an inflammatory arthritis model. Cadherin 11 is minimally expressed in immune cells (113) , and anti-cadherin 11 antibody reduces arthritis severity in mice (114) . A humanized monoclonal antibody targeting cadherin 11 has been evaluated in a phase I tolerability study (115) ( Table 4) . As synoviocyte proliferation features prominently in synovial pathology, interference in cell cycle regulation TUMOR-LIKE PHENOTYPE OF RA SYNOVIUM 647 may be a promising therapeutic intervention. Smallmolecule inhibitors of cyclin-dependent kinases (CDKs), which regulate cell cycle progression at the G 1 /S phase transition, have been developed as anticancer therapies (116) ( Table 4) . Both alvocidib, a pan-CDK inhibitor, and palbociclib, a selective CDK-4/6 inhibitor, ameliorate arthritis in a murine model (117, 118) . Combination therapy with cytokine blockade and palbociclib also shows a synergistic antiarthritic effect (117) ( Table 4) . Rheumatoid synovium has been targeted by radionuclide synovectomy (119) . In one approach, a colloidal solution of a b-emitting radioactive agent is injected intraarticularly so that the particles are phagocytized by the synovial lining cells, which concentrates the b-energy within pannus (120) . Yttrium-90 citrate has been the most widely studied agent (120, 121) , but phosphate-32, rhenium-186, and erbium-169 citrate also have been tested (122) . Although the injected radionuclide affects immune cells within the synovium, the localized activity of the radionuclide may curtail stromal hyperplasia without influencing systemic immunity. In a related approach using non-radionuclides, the cytotoxic action of cadmium on synoviocytes was tested. Cadmium injection into rat joints improved arthritis, reduced inflammatory cell recruitment, and protected against bone/cartilage destruction. The investigators suggest that the limited systemic dispersion of cadmium and an auspicious safety profile support exploration of this approach (123) . Pharmacologic strategies directed at DNA methylation and histone modification are under increasing study in different diseases, and hold interest given the likely epigenetic basis for the sustained aggressive phenotype of rheumatoid synoviocytes (124) . Targeting synoviocyte-specific proteins or the cell cycle could inhibit proliferative pathways in early or established RA (117), whereas targeting epigenetic modification could additionally affect asymptomatic autoimmunity.
Neidhart et al have proposed that inhibition of the polyamine recycling pathway with diminazene aceturate, an inhibitor of spermidine/spermine N1-acetyltransferase that increases cellular 5-methylcytosine and DNA methyltransferase 1 levels, may restore DNA methylation in rheumatoid synovium. This agent alone or in combination 40406/abstract. FLS = fibroblast-like synoviocytes; RA = rheumatoid arthritis; CDK = cyclin-dependent kinase; CIA = collagen-induced arthritis; CII = type II collagen; IL-6 = interleukin-6; FDA = Food and Drug Administration; GI = gastrointestinal; SSAT-1 = spermidine/spermine N1-acetyltransferase 1; MMP-1 = matrix metalloproteinase 1; SAHA = suberoylanilide hydroxamic acid; JIA = juvenile idiopathic arthritis; QTc = corrected QT interval.
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with S-adenosyl methionine reduces adhesive character and MMP1 expression, as well as the invasiveness, of synoviocytes implanted into immunodeficient mice (124, 125) . Pharmacologic HDAC inhibitors are under investigation as antineoplastic agents and have been evaluated in preclinical and clinical studies in RA (Table 4) . Inhibition of HDAC activity by various HDAC inhibitors, such as givinostat, suberoylanilide hydroxamic acid, MS-275, trichostatin A, and FK228, ameliorates joint inflammation and prevents cartilage and bone destruction in experimental models of inflammatory arthritis (125) . Notably, a clinical trial of givinostat in patients with systemic-onset juvenile idiopathic arthritis resistant to standard treatment has been reported recently and showed therapeutic benefit with an excellent safety profile (126) ( Table 4 ). If acquired mutations feature prominently in the perpetuation of synovial aggressiveness, approaches to selectively kill or incapacitate rheumatoid FLS may prove difficult. All such approaches nevertheless will benefit from a closer molecular definition of RA disease "subphenotypes," and a precision-based therapeutic approach similar to what is being achieved in anticancer pharmacology ultimately may be attainable.
Conclusions
While definitive human genetic or experimental data remain to be acquired, germline or acquired mutations in synoviocytes likely contribute to RA susceptibility, progression from pre-RA to frank disease, and clinical severity. Genetic factors, working over time and in concert with environmental factors, contribute to the epigenetic alterations that appear responsible for the sustained and aggressive phenotype of rheumatoid FLS. Defining pathologic relationships among RA risk alleles, profiling databases, and characterizing pathologic synoviocyte phenotypes may enable better understanding of the molecular basis for the aggressive transformation of rheumatoid FLS. Limitations in the current omics databases with respect to annotation, sample sources, and data quality presently restrict any comprehensive or complementary reconstruction of pathways that may provide pathologic insight and avenues for therapeutic development. Nevertheless, the thoughtful application and integration of genomic, epigenomic, proteomic, and metabolomic technologies should ultimately yield these insights. The immunopathologic contribution of rheumatoid synoviocytes to eventual joint destruction appears highly significant, and the stromal origin of these cells may render them intrinsically resistant to current immunotherapies. Similar limitations exist in our therapeutic approaches to inflammatory fibrosing disorders such as systemic sclerosis, in which activated connective tissue cells have a central pathologic role. If RA synovium delivers cues for perpetuating autoimmunity, then the therapeutic targeting of synoviocytes may offer a powerful approach for long-term remission (if not cure) and the possibility of intervention in the most disabling and morbid features of the disease.
